Early Detection Research Network (EDRN) Program for Rapid, Independent Diagnostic Evaluation (PRIDE) for Cancer Biomarkers

Description:
Through its resources for serum reference samples, technologies, informatics, and reference laboratories on validation, the Early Detection Research Network (EDRN) supports investigators by helping them with rapid evaluations of the reproducibility, portability, and precision of their technologies and biomarker assays. EDRN hereby announces the establishment of the Program for Rapid, Independent Diagnostic Evaluation (PRIDE), which is an administrative means by which it can assist extramural investigators in the successful conduct of cross-laboratory validations of biomarkers, including the development, refinements, and uses of new and existing assays, reagents, methods, and tests.

Web Site:


Availability:
Interested investigators are invited to submit two- to three-page-long (maximum) descriptions of their biomarkers that meet the criteria for Phase II or Phase III validations as described in the Journal of the National Cancer Institute 93(4), 1054 -1061, 2001. Request-for-validation-support letters containing descriptions of biomarkers meeting the eligibility criteria are accepted on a continuous basis throughout the year.

Cost:
Funding for PRIDE will be provided through the EDRN's Set-Aside funds for biomarker validations.

Contact:
Donald Johnsey; johnseyd@mail.nih.gov

This page last updated 2006-11-03 16:26:38